Fortress Biotech (FBIO) Corporate presentation summary

Strategic focus and business model

• Focuses on commercial dermatology and acquiring/developing clinical-stage assets in rare diseases, oncology, and dermatology.

• Employs a diversified model with multiple revenue streams, including product sales, royalties, equity dividends, and monetization events.

• Leverages market inefficiencies and global arbitrage to acquire validated clinical candidates and ex-US approved drugs on favorable terms.

• Provides operational, strategic, and financial support to subsidiaries and partner companies, sharing resources and expertise.

Portfolio highlights and recent milestones

• Achieved three FDA approvals since Q4 2024, including Emrosi for rosacea, Unloxcyt for cSCC, and Zycubo for Menkes Disease.

• Sold a Priority Review Voucher for Zycubo for $205M and is eligible for up to $128M in sales milestones and tiered royalties.

• Closed the sale of Checkpoint Therapeutics to Sun Pharma, receiving $28M upfront, potential $4.8M CVR, and 2.5% royalty on Unloxcyt sales.

• Urica Therapeutics sold dotinurad to Crystalys, retaining equity and a 3% royalty; Crystalys raised $205M for Phase 3 trials.

Development pipeline and commercial portfolio

• Portfolio includes 8 FDA-approved dermatology products and 14 clinical/preclinical candidates across 20+ indications.

• Key marketed products: Emrosi, Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm, Targadox, Luxamend.

• Late-stage assets: Unloxcyt (cSCC), Zycubo (Menkes), CAEL-101 (AL amyloidosis), Dotinurad (gout), Triplex (CMV/HIV/NHL).

• Early/mid-stage pipeline includes candidates for Pompe disease, glioblastoma, epilepsy, Duchenne muscular dystrophy, and more.